Evidence map›Paper›PMID 33747357›Full record

ArticleOncotarget2021

The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy.

H M C Shantha Kumara, Elie Sutton, Otavia L Caballero, Tao Su, Xiaohong Yan, Aqeel Ahmed, Sonali A C Herath, Vesna Cekic, Linda Njoh, Daniel D Kirchoff and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 1 country.

H M C Shantha KumaraDivision of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY 10028, USA.
Elie SuttonDepartment of Surgery, Mount Sinai West Hospital, New York, NY 10019, USA.
Otavia L CaballeroLudwig Institute for Cancer Research Ltd., New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering, New York, NY, USA.
Tao SuHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Xiaohong YanDivision of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY 10028, USA.
Aqeel AhmedHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Sonali A C HerathUniversity of Vermont Medical Center, Internal Medicine Hospitalist Service, Burlington, VT 05401, USA.
Vesna CekicDivision of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY 10028, USA.
Linda NjohDepartment of Mathematics, City University of New York at Lehman College, Bronx, NY 10468, USA.
Daniel D KirchoffRoper St. Francis Physician Partners Surgical Oncology, Charleston, SC 29403, USA.
Richard L WhelanDivision of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY 10028, USA.
Columbia University Irving Medical Center · USLenox Hill Hospital · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USLehman College · USLudwig Cancer Research · USMount Sinai Hospital · USNorthwell Health · USRoper St. Francis Healthcare · USUniversity of Vermont Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionCalcium-binding tyrosine phosphorylation-regulated protein (CABYR) is expressed in the human germ line but not in adult human tissues, thus, it is considered a cancer testis protein. The aim of this study is to evaluate the CABYR isoforms: a/b and c mRNA expression in colorectal cancer (CRC) and to determine if these proteins hold promise as vaccine targets. MATERIALS AND

methodsCABYR mRNA expression in a set of normal human tissues, including the testis, were determined and compared using semi-quantitative PCR. As regards the tumor and normal mucosal samples from study patients, RNA was extracted and cDNA generated after which quantitative PCR was carried out. Analysis of CABYR protein expressions by immunohistochemistry in tumor and normal colon tissues was also performed.

resultsA total of 47 paired CRC and normal tissue specimens were studied. The percent of patients with a relative expression ratio of malignant to normal (M/N) tissues over 1 was 70% for CABYR a/b and 72% for CABYR c. The percent with both a M/N ratio over 1 and expression levels over 0.1% of testis was 23.4% for CABYR-a/b and 25.5% for CABYR c. CABYR expression in tumors was further confirmed by immunohistochemistry.

conclusionsCABYR a/b and c hold promise as specific immunotherapy targets, however, a larger and more diverse group of tumors (Stage 1-4) needs to be assessed and evaluation of blood for anti-CABYR antibodies is needed to pursue this concept.

Indexed as

CABYR a/b, ccancer testis antigenscolorectal cancer

Identifiers

PMID33747357
PMCPMC7939523
OpenAlexW3133597426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.